SCHEMBL2902674

SCHEMBL2902674

CCN(CC)C(c1ccc(-c2cccc(F)c2)cc1)c1c[nH]nc1-c1ccco1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3R1 P27986 3/20 0.38
PIK3CA P42336 3/20 0.38
CLK4 Q9HAZ1 1/20 0.32
FFAR1 O14842 1/20 0.32
LCLAT1 Q6UWP7 1/20 0.31
PRNP P04156 2/20 0.31
USP2 O75604 1/20 0.31
POLB P06746 1/20 0.31
MEN1 O00255 1/20 0.31
GAA P10253 1/20 0.31
KMT2A Q03164 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
CYP17A1 P05093 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP11B1 P15538 1/20 0.31
CYP11B2 P19099 1/20 0.31
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2901803 0.91 PIK3R1 (0.35) PIK3R1PIK3CAMEN1GAAKMT2A
SCHEMBL2902807 0.84 ALDH1A1 (0.38) USP2POLBMEN1GAAKMT2A
SCHEMBL2901868 0.77 PIK3R1 (0.39) PIK3R1PIK3CACLK4PRNPUSP2
SCHEMBL2902613 0.76 PIK3R1 (0.37) PIK3R1PIK3CAPOLBMEN1GAA
SCHEMBL2903067 0.76 OPRD1 (0.37) PIK3R1PIK3CAMEN1KMT2A
SCHEMBL2902357 0.74 HRH3 (0.37) PIK3R1PIK3CAUSP2POLBMEN1
Morpholine SCHEMBL2905731 0.73 OPRD1 (0.35) PIK3R1PIK3CAPOLBTP53MAPT
SCHEMBL2908848 0.72 LRRK2 (0.36) PIK3R1PIK3CAMAPTLMNA
SCHEMBL2910374 0.72 ALDH1A1 (0.41) PIK3R1PIK3CAUSP2GAAKMT2A
SCHEMBL2904791 0.70 CYP3A4 (0.42) USP2GAACYP3A4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A PIK3R1 2479/4885PIK3CA 3500/4885CLK4 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.